超碰97人人爱人人做-超碰97人人操-超碰97人人操人人干-超碰97人人操人人摸-超碰97人人艹-超碰97人人干人人爱

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日韩精品一线二线三线优势 | 国产另类巨| 亚洲午夜在线x88∨ 欧美自拍另类欧美综合图片区 | 国产自产一二三区 | 国产欧色美视频综合二区 | 欧美一区二区手机在线观看视频 | 国产免费高清69式视频在线观看 | 九九视频国产免 | 亚洲一区在线 | 国产乱码精品一品二品 | 日韩国产欧美在线观 | 女被男啪到哭的视频网站 | 国产精品99精品 | 精品国产一区二区三区 | 欧美鲁丝片一区二区 | 51精品国产人成在线观看 | 亚洲aⅴ欧洲国产aⅴ | 中文字幕在线精品男人的天堂 | 日本中文字幕在线免费观看视 | 亚洲欧美日韩综合在线一区二 | 日本一区二区不卡中文字幕 | 亚洲人成色7777在线观看 | 一日本道伊| 欧美网站免费观看在线 | 国产二三区 | 日本大片免a费观看视频 | 日韩专区亚洲精品 | 日韩欧美一区二 | 99九九视频高清在线 | 99精品自拍偷拍一区二区 | 国产激情一区在线观 | 日本人妖| 日韩一三区在 | 国产福利一区二区三区在线 | 国产呦精品一区二区三区网站 | 岛国一区二区三区在线 | 国产午夜三级 | 国产午夜福利片在线播放 | 美国特黄三级完整在线电 | 亚洲欧洲另类春色校园小说 | 欧美日韩国产亚洲一区二区 |